The Latest Cardiac and Vascular News
Conference Call and Webcast at 5:00 pm Eastern Time THE WOODLANDS, Texas, May 06, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2021 and provided an update on key milestones. “We continue to enroll patients in our two proof-of-concept Phase 2 clinical studies for LX9211 […]
THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application (NDA) submission for an indication to reduce the risk of cardiovascular […]
